News
GLAXF
27.08
+2.58%
0.68
Regeneron Pharmaceuticals: Q1 Beat Driven By Dupixent And Eylea HD Strength
Seeking Alpha · 18h ago
Stock Index Futures Gain on Tech Boost Ahead of Fed Decision and Big Tech Earnings
Barchart · 1d ago
Weekly Report: what happened at GLAXF last week (0420-0424)?
Weekly Report · 2d ago
AnaptysBio: 'Hold' As Spin-Off Shifts Pipeline To First Tracks Biotherapeutics
Seeking Alpha · 04/21 19:02
Gilead Sciences: Why I'm Tempted To Sell Ahead Of Q1 Earnings - But Won't
Seeking Alpha · 04/20 19:59
What To Expect From Sanofi In Q1 2026
Seeking Alpha · 04/20 13:28
Weekly Report: what happened at GLAXF last week (0413-0417)?
Weekly Report · 04/20 10:00
GSK: 'Strong Buy' On Mo-Rez Oncology Expansion Potential
Seeking Alpha · 04/19 11:42
Weekly Report: what happened at GLAXF last week (0406-0410)?
Weekly Report · 04/13 10:03
Weekly Report: what happened at GLAXF last week (0330-0403)?
Weekly Report · 04/06 10:04
GSK: Chinese Expansion And Fine Financials
Seeking Alpha · 03/31 12:00
Weekly Report: what happened at GLAXF last week (0323-0327)?
Weekly Report · 03/30 10:04
Weekly Report: what happened at GLAXF last week (0316-0320)?
Weekly Report · 03/23 10:00
Routine Vaccines Okay For Now: Investment Implications Of The Court Decision
Seeking Alpha · 03/18 13:45
GSK Expanding Fast - Oncology, HIV, And Smart Acquisitions
Seeking Alpha · 03/18 12:00
Weekly Report: what happened at GLAXF last week (0309-0313)?
Weekly Report · 03/16 10:00
Weekly Report: what happened at GLAXF last week (0302-0306)?
Weekly Report · 03/09 10:01
Weekly Report: what happened at GLAXF last week (0223-0227)?
Weekly Report · 03/02 10:00
Electromed: Some Short Term Gain But I Fear Long Term Pain
Seeking Alpha · 02/24 03:35
Weekly Report: what happened at GLAXF last week (0216-0220)?
Weekly Report · 02/23 10:00
More
Webull provides a variety of real-time GLAXF stock news. You can receive the latest news about GSK PLC through multiple platforms. This information may help you make smarter investment decisions.
About GLAXF
GSK plc is a United Kingdom-based biopharma company. The Company’s segments include Commercial Operations and Research and Development. The Company is focused on the science of the immune system and advanced technologies, investing in four core therapeutic areas-respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from asthma, cancer and HIV to autoimmune diseases like lupus. General medicines include inhalers for asthma and chronic obstructive pulmonary disease (COPD) with antibiotics. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development. The Company also engaged in ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody. The Company also owns HS235, a potential molecule for the treatment of pulmonary hypertension (PH).